Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium

SAN DIEGO, Nov. 7, 2024 /PRNewswire/ — Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting…